About Code Biotherapeutics
Code Biotherapeutics is a company based in Hatfield (United States) founded in 2020 by Robert C Getts.. Code Biotherapeutics has raised $85 million across 2 funding rounds from investors including Amgen, UPMC and Takeda Pharmaceuticals. Code Biotherapeutics offers products and services including 3DNA Platform. Code Biotherapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Hatfield, United States
- Founders Robert C Getts
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$85 M (USD)
in 2 rounds
-
Latest Funding Round
$75 M (USD), Series A
Jun 07, 2022
-
Investors
Amgen
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Code Biotherapeutics
Code Biotherapeutics offers a comprehensive portfolio of products and services, including 3DNA Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables targeted delivery of genetic medicines to overcome toxicity and targeting issues.
Unlock access to complete
Unlock access to complete
Funding Insights of Code Biotherapeutics
Code Biotherapeutics has successfully raised a total of $85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $75 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $75.0M
-
First Round
First Round
(20 Apr 2021)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series A - Code Biotherapeutics | Valuation | Northpond Ventures | |
| Apr, 2021 | Amount | Seed - Code Biotherapeutics | Valuation | 4Bio Capital , UPMC |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Code Biotherapeutics
Code Biotherapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, UPMC and Takeda Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Founded Year | Domain | Location | |
|
UCB Ventures is focused on strategic corporate venture investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Code Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Code Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Code Biotherapeutics Comparisons
Competitors of Code Biotherapeutics
Code Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Code Biotherapeutics
Frequently Asked Questions about Code Biotherapeutics
When was Code Biotherapeutics founded?
Code Biotherapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Code Biotherapeutics located?
Code Biotherapeutics is headquartered in Hatfield, United States.
Is Code Biotherapeutics a funded company?
Code Biotherapeutics is a funded company, having raised a total of $85M across 2 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Apr 20, 2021.
What does Code Biotherapeutics do?
Founded in 2020, Code Biotherapeutics operates in the biotechnology sector, focusing on gene therapies for rare conditions such as Duchenne muscular dystrophy and type 1 diabetes. A proprietary non-viral platform, 3DNA, is utilized to deliver genes of varying sizes, enhance cellular targeting, and minimize immunogenicity. The company is based in Hatfield, United States, with efforts centered on advancing these treatments through research and development.
Who are the top competitors of Code Biotherapeutics?
Code Biotherapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Code Biotherapeutics offer?
Code Biotherapeutics offers 3DNA Platform.
Who are Code Biotherapeutics's investors?
Code Biotherapeutics has 12 investors. Key investors include Amgen, UPMC, Takeda Pharmaceuticals, CureDuchenne Ventures, and Northpond Ventures.